100 Days Mission - Fifth Implementation Report Launch 

The 100 Days Mission

The cornerstone of the 100DM is to establish a procedure for making safe, effective and affordable diagnostics, treatments and vaccines (DTVs) available for mass production within 100 days of the identification of a public health emergency of international concern (PHEIC).

This mission was launched in July 2021 by the Wellcome Trust and Bill & Melinda Gates Foundations, in agreement with the leaders of the G7 countries. It is led by an independent body, the IPPS, composed of researchers, public health policy-makers and representatives of the private sector, in coordination with the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), the G20 countries and the World Health Organisation (WHO). The IPPS produces an annual implementation report to track the progress of the 100DM, examine the obstacles that still stand in its way and explore options for action in 2026 – the year in which the mission is due to expire.

Background

In 2025, we saw progress in epidemic preparedness, notably with the adoption of the Pandemic Agreement at the last WHO World Health Assembly in May. However, the world has also been hit by several outbreaks of H5N1, dengue, chikungunya, Ebola and Rift Valley fever, has seen new cases and a resurgence of measles and whooping cough, while mpox remains a health emergency on the African continent.

This is a sad reminder of the urgent need for collective preparedness at the national, regional and global levels. As the International Pandemic Preparedness Secretariat (IPPS) enters its final year, the question remains: are we really making progress in establishing rapid access to the VDTs needed to address these converging threats to global security?

About the event

On 27 January, the fifth 100DM report from the IPPS will present the main conclusions drawn from 2025, examine the obstacles that still hinder progress and explore opportunities for action in 2026. All this while France hosts the next One Health Summit in Lyon in April and then chairs the G7 in Evian-les-Bains in June, as the world prepares for the United Nations High-Level Meeting on Pandemic Prevention, Preparedness and Response (PPPR) scheduled for September 2026.

This event will:

• Publicly launch the 2025 Implementation Report and 100 Days Mission Scorecard 3.0, outlining progress in DTV development and priority actions for 2026.
• Strengthen cross-pillar alignment across diagnostics, therapeutics, vaccines, clinical trials and regulatory systems.
• Catalyse collaboration around the Therapeutics Development Coalition (TxDC) ahead of its Spring 2026 launch.
• Build consensus around investment and innovation priorities emerging from the 2025 Global Diagnostics Gap Assessment.
• Advance dialogue on vaccine equity, regional production and distributed manufacturing.
• Illustrate the societal value of preparedness, from innovation and job creation to strengthened health systems.

Programme

09:00–09:30

Welcome & Opening Remarks 

Speakers:

• Dr Mona Nemer, Chair of IPPS; Chief Science Advisor of Canada 
• Prof Didier Samuel, Chairman and CEO of Inserm 
• Dr Yazdan Yazdanpanah, Director of ANRS MIE  
• Dr Rebecca Grais, Executive Director, Pasteur Network  
• Ms Anne-Claire Amprou, Global Health Ambassador France 

09:30–10:30 – Session 1 

100 Days Mission Fifth Implementation Report Findings 

This session brings together members of the IPPS Science & Technology Expert Group (STEG) and IPPS Steering Group to present the key findings of the Fifth Implementation Report. Speakers will examine how diagnostics, therapeutics, vaccines, clinical trials and regulatory systems must work in concert—not in silos—to accelerate innovation and deployment. 

Speakers:

• Ms Shingai Machingaidze, IPPS STEG Co-chair; Head of Africa Strategy and Engagement at CEPI (moderator) 
• Dr Victor Dzau, IPPS STEG Co-chair; President, US National Academy of Medicine 
• Dr Lindsay Keir, Incoming Programme Director, G20 & G7 Health and Development Partnership /   Former Director of Science and Policy, Impact Global Health 
• Dr François Lacoste, IPPS STEG; Executive Vice President, Medical and Scientific Affairs, Institut Mérieux 
• Dr Hala Audi, IPPS STEG; Chief Alliance Officer of Quantoom Biosciences 
• Dr Moeketsi Modisenyane, Director of Global Health, National Department of Health, South Africa (virtual) 
• Dr Morwenna Carrington, Deputy Director, UK Health Security, DHSC 

10:30–10:45 – Refreshment Break 

10:45–11:45 – Session 2 

Closing the Gap in R&D: Building a Global Development Coalition for Therapeutics 

Therapeutics remain one of the most underdeveloped components of the 100 Days Mission. This session will outline the goals of the Therapeutics Development Coalition (TxDC) and highlight how a coordinated global approach can accelerate antiviral innovation, strengthen collaboration, and support equitable access. 

Speakers:

• Dr Victor Dzau, IPPS STEG Co-chair; President, US National Academy of Medicine (Moderator) 
• Dr Philippe Duneton, Executive Director of Unitaid (Moderator) 
• Dr Lynda Stuart, IPPS STEG; Fund for Science and Technology 
• Mr Laurent Muschel, Director General, HERA, European Commission  
• Dr Ruxandra Draghia-Akli, IPPS STEG; Head of R&D, Novavax Inc 
• Dr Kelly Chibale, IPPS STEG; Professor of Organic Chemistry, University of Cape Town, H3D Centre (virtual) 

11:45–12:45 – Session 3  

Diagnostics: The First Line of Defence for Health 

Drawing from the 2025 Global Diagnostics Gap Assessment, this panel will explore how to close persistent gaps in funding, coordination, innovation, and deployment. Speakers will discuss how diagnostics can be better integrated with vaccines and therapeutics for a coherent preparedness architecture. 

Speakers:

• Dr Mona Nemer, Chair of IPPS; Chief Science Advisor of Canada (moderator) 
• Dr Dayo Adetifa, CEO, FIND  
• Dr Beth Cameron, Senior Adviser, Brown University Pandemic Centre; HLIP 
• Prof Bruno Lina, Président du Infectious Diseases Cluster 
• Prof Leo Poon, Co-Director, Hong Kong University (HKU)- Pasteur 
• Dr Hervé Raoul, Deputy Director, ANRS MIE 

12:45–13:45 – Lunch Break 

13:45–14:45 – Session 4 

Turning Innovation into Impact: Advancing Vaccine Equity 

This session examines how scientific innovation can be translated into equitable vaccine access, with a focus on regional production, distributed manufacturing, and the new Global Coalition on Regional Production, Innovation and Access. 

Speakers:

• Dr Rick Bright, IPPS STEG; Bright Global Health (moderator) 
• Prof Mario Santos Moreira, IPPS Steering Group; Pasteur Network; Fiocruz 
• Dr Melanie Saville, Chief Scientific Officer, PATH 
• Dr Eric Quéméneur, Director of France Vaccins, Inserm 
• Dr Aurélia Nguyen, Deputy CEO, CEPI 
• Prof Abderrahmane Maaroufi, Director Institut Pasteur du Maroc 
• Dr Katherine Theiss Nyland, Senior Director Global Real World Evidence & Health Outcomes, GSK 

14:45–15:45 – Session 5 

From Global Commitment to Local Prosperity: Driving Impact Through Preparedness 

Preparedness drives long-term societal value—from innovation ecosystems and job creation to resilient health systems. This session explores how investments in DTVs and emerging technologies can deliver national benefits while strengthening global readiness. 

Speakers:

• Ms Eloise Todd, Executive Director, Resilience Action Network International (rani) (moderator) 
• Ms Shingai Machingaidze, IPPS STEG Co-chair; Head of Africa Strategy and Engagement at CEPI 
• Dr Kerri Elgar, Senior Policy Analyst (Global Health & Development) OECD 
• Dr Claire Rieux, Medical Director, Médecins Sans Frontières France 

15:45–16:00 — The Way Forward 

Closing remarks from Dr Mona Nemer, Chair of IPPS and Chief Science Advisor of Canada